Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition

ABSTRACT PTPN12 is a cytoplasmic protein tyrosine phosphatase (PTP) reported to be a tumor suppressor in breast cancer, through its capacity to dephosphorylate oncogenic receptor protein tyrosine kinases (PTKs), such as ErbB2. However, the precise molecular and cellular impact of PTPN12 deficiency in breast cancer progression remains to be fully clarified. Here, we addressed this issue by examining the effect of PTPN12 deficiency on breast cancer progression in vivo, in a mouse model of ErbB2-dependent breast cancer using a conditional PTPN12-deficient mouse. Our studies showed that lack of PTPN12 in breast epithelial cells accelerated breast cancer development and lung metastases in vivo. PTPN12-deficient breast cancer cells displayed enhanced tyrosine phosphorylation of the adaptor Cas, the adaptor paxillin, and the kinase Pyk2. They exhibited no detectable increase in ErbB2 tyrosine phosphorylation. PTPN12-deficient cells were more resistant to anoikis and had augmented migratory and invasive properties. Enhanced migration was corrected by inhibiting Pyk2. PTPN12-deficient breast cancer cells also acquired partial features of epithelial-to-mesenchymal transition (EMT), a feature of more aggressive forms of breast cancer. Hence, loss of PTPN12 promoted tumor progression in a mouse model of breast cancer, supporting the notion that PTPN12 is a tumor suppressor in human breast cancer. This function was related to the ability of PTPN12 to suppress cell survival, migration, invasiveness, and EMT and to inhibit tyrosine phosphorylation of Cas, Pyk2, and paxillin. These findings enhance our understanding of the role and mechanism of action of PTPN12 in the control of breast cancer progression.

[1]  E. Giannoni,et al.  Anoikis: an emerging hallmark in health and diseases , 2012, The Journal of pathology.

[2]  S. Latour,et al.  EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization , 2014, The Journal of experimental medicine.

[3]  M. Tremblay,et al.  Protein Tyrosine Phosphatase-PEST Regulates Focal Adhesion Disassembly, Migration, and Cytokinesis in Fibroblasts , 1999, The Journal of cell biology.

[4]  M. Rao,et al.  Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase , 2011, Cell.

[5]  H. Tian,et al.  PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker , 2013, Medical Oncology.

[6]  Tony Pawson,et al.  Temporal regulation of EGF signaling networks by the scaffold protein Shc1 , 2013, Nature.

[7]  J. Yun,et al.  The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma , 2015, Tumor Biology.

[8]  J Wagner,et al.  Phosphotyrosine-independent Binding of SHC to the NPLH Sequence of Murine Protein-tyrosine Phosphatase-PEST , 1996, The Journal of Biological Chemistry.

[9]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Inmoo Rhee,et al.  The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. , 2010, Immunity.

[11]  Dana M. Brantley-Sieders,et al.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. , 2008, The Journal of clinical investigation.

[12]  Inmoo Rhee,et al.  Control of Dendritic Cell Migration, T Cell-Dependent Immunity, and Autoimmunity by Protein Tyrosine Phosphatase PTPN12 Expressed in Dendritic Cells , 2013, Molecular and Cellular Biology.

[13]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[14]  R. Cardiff,et al.  PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis* , 2009, The Journal of Biological Chemistry.

[15]  Michael D Schaller,et al.  Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions , 2010, Journal of Cell Science.

[16]  S. Hardy,et al.  Inside the human cancer tyrosine phosphatome , 2010, Nature Reviews Cancer.

[17]  W. Muller,et al.  Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis , 2011, Proceedings of the National Academy of Sciences.

[18]  E. Pasquale,et al.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer. , 2012, Genes & cancer.

[19]  Xunyi Yuan,et al.  Clinicopathological significance of PTPN12 expression in human breast cancer , 2012, Brazilian Journal of Medical and Biological Research.

[20]  M. Tremblay,et al.  Essential function of PTP-PEST during mouse embryonic vascularization, mesenchyme formation, neurogenesis and early liver development , 2006, Mechanisms of Development.

[21]  P. Defilippi,et al.  Cas proteins: dodgy scaffolding in breast cancer , 2014, Breast Cancer Research.

[22]  Jia Fu,et al.  Decreased Expression of PTPN12 Correlates with Tumor Recurrence and Poor Survival of Patients with Hepatocellular Carcinoma , 2014, PloS one.

[23]  A. Veillette,et al.  PTP‐PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates , 2001, The EMBO journal.

[24]  V. Paralkar,et al.  Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis , 2007, Proceedings of the National Academy of Sciences.

[25]  J. Vacher,et al.  Macrophage Fusion Is Controlled by the Cytoplasmic Protein Tyrosine Phosphatase PTP-PEST/PTPN12 , 2013, Molecular and Cellular Biology.

[26]  G Melino,et al.  PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling , 2014, Oncogene.

[27]  Z. Wen,et al.  Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer , 2015, Oncotarget.

[28]  J. Gratton,et al.  The Phosphatase PTP-PEST/PTPN12 Regulates Endothelial Cell Migration and Adhesion, but Not Permeability, and Controls Vascular Development and Embryonic Viability* , 2012, The Journal of Biological Chemistry.

[29]  M. Tremblay,et al.  Combination of gene targeting and substrate trapping to identify substrates of protein tyrosine phosphatases using PTP-PEST as a model. , 1998, Biochemistry.

[30]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[31]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[32]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[33]  K. Siminovitch,et al.  Nonreceptor protein-tyrosine phosphatases in immune cell signaling. , 2007, Annual review of immunology.

[34]  Francesca Orso,et al.  p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells , 2012, Breast Cancer Research.

[35]  Qidong Ge,et al.  Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[36]  T. Pawson,et al.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.

[37]  Michael A. Bookman,et al.  The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56 lck , 1988, Cell.

[38]  C. M. Souza,et al.  PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders , 2009, Immunological reviews.